Halaven Wins FDA Approval as Third-Line Breast Cancer Treatment

More than a month before its user fee action date, the FDA has approved Eisai’s late-stage breast cancer treatment Halaven. The drug is indicated to treat metastatic breast cancer in patients who have failed at least two prior chemotherapy regimens, such as anthracycline- and taxane-based therapies. Eisai spokeswoman Judee Shuler did not disclose the drug’s price but noted it reflects the value it provides to patients.
Washington Drug Letter